Abstract. We examined the association of a 34-kD light chain component to the heavy chains of MAP-1 using a monoclonal antibody that specifically binds the 34-kD component and labels neuronal microtubules in a specific and saturable manner. Immunoprecipitation of MAP-1 heavy chains together with the 34-kD component by the antibody indicates that the 34-kD polypeptide forms a complex with MAP-1 heavy chains. Both major isoforms of MAP-1 heavy chains (MAP-1A and MAP-1 B) were found in the immunoprecipitate. Digestion of MAP-1 with alphachymotrypsin and analysis of the chymotryptic peptides reveals a 120-kD fragment of the MAP-1 heavy chain that binds to microtubules and is precipitable with the 34-kD light chain antibody, suggesting that the 34-kD light chain also binds to this domain of the molecule. Since microtubules that contain the 120-kD fragment lack the long lateral projections characteristic of microtubules with intact MAP-l, the 34-kD light chains may be localized at or near the microtubule surface.
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M
ICROTUBULES isolated from brain tissue extracts are composed of tubulin plus several microtubule-associated proteins (MAPs). ~ Of these, two classes of high molecular weight components termed MAP-1 and MAP-2 have been demonstrated to co-purify with tubulin during cycles of microtubule assembly and disassembly and to stimulate microtubule assembly in vitro (for a review see reference 22) . There is considerable evidence that MAPs may mediate the binding of membranous organelles, actin filaments, and intermediate filaments to microtubules, leading to the speculation that they may therefore be important for cellular processes such as mitosis and organelle transport, and for determining the dynamic properties of the cytoskeleton. Immunofluorescence microscopic studies on the distribution of the brain high molecular weight MAPs have shown that MAP-2 is localized primarily in the dendrites of neurons in brain (2, 12) and possibly in small amounts in other cells (6, 17, 23) , most notably chromatophores (18) . In contrast, MAP-1 is more generally distributed, being found in both dendrites and axons of neurons and in glial cells in brain, in chromatophores, and on both interphase and mitotic microtubules in various tissue culture cells, suggesting that MAP-1 may have a more general function (1, 18) .
Recently MAP-I has been isolated and demonstrated to stimulate tubulin assembly in vitro (7, 8, 21) and to exhibit structural characteristics similar to those of MAP-2 as 20-nm Abbreviations used in this paper." LC-1, LC-2, light chains 1 and 2 of MAP-1; MAP, microtubule-associated protein; PMSF, phenylmethylsulfonyl fluoride. long projections on microtubule surfaces (9, 21) . Purified preparations of MAP-I from bovine brain have also been demonstrated to contain at least two low molecular weight components that remain tightly associated with MAP-1 heavy chains during ion-exchange chromatography and during gel filtration chromatography under nondenaturing conditions. The stoichiometric ratio of both light chains to one MAP-1 heavy chain is approximately 1:1 (21 ) .
In this paper we examine further the relationship of the low molecular weight components to MAP-1 heavy chain using a monoclonal antibody to the larger of the two light chain components and describe the location of this polypeptide on a microtubule-binding, chymotryptic peptide of the MAP-l heavy chain at or near the microtubule surface.
Materials and Methods

Biochemical Procedures
Microtubules, MAPs, MAP-I, and tubulin were purified from bovine brain in a buffer containing 50 mM imidazole-HCl (pH 6.7), 50 mM KC1, 0.5 mM MgCI2, 0.1 mM EDTA, 1 mM GTP, 1 mM 2-mercaptoethanol (buffer A) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF). Unfractionated microtubule proteins were prepared by two cycles of assembly-disassembly (16) as modified by Rodionov et al. (14) . Tubulin and MAPs were separated by chromatography on phosphocellulose in buffer A with 1 mM PMSF (25) .
MAP-I was purified as described in reference 7. Purified MAP-I was often contaminated with polypeptides of lower molecular weight, including polypeptides that co-migrated with MAP-2 during SDS PAGE (see, for example, Fig.  1 , lane C and Fig. 6A , 0 rain). These polypeptides accumulated in preparations during storage, suggesting that they are products of MAP-l proteolysis. Im-munoblotting with a monoclonal antibody to MAP-2 (see below) never showed this polypeptide or its degradation products in purified MAP-I preparations.
Microtubule-hinding activity of the MAPs and their proteolytic fragments was determined by a sedimentation assay in the presence of microtubules. Samples of total MAPs or purified MAP-I were clarified by centrifugation at 150,000 g for 30 min. Microtubules were prepared by polymerizing phosphocellulose-purified tubulin (0.8-1.0 mg/ml) at 37"C for 30 min in buffer A supplemented with 10 t*M taxol, 1 mM GTP, and 1 mM EGTA. Microtubule assembly was monitored by light scattering at 330 nm (3) . The fraction to be tested was added to the taxol-microtubules (1:10 MAP peptide/tubulin ratio), and after 30 min of incubation at 37"C, microtubules were pelleted for 30 min at 200,000 g (SW 50.1 rotor, Beckman Instruments Inc., Palo Alto, CA) through a cushion of 4 M glycerol in buffer A with 1 mM EGTA. The pellets were solubilized in 1% SDS and analyzed by SDS PAGE. A 33 kD-protein that inhibits tubulin polymerization was purified from bovine brain according to Kotani et al. (4) . Another 35-kD microtubule-binding protein (glyceraldehyde-3-phosphate dehydrogenase) was prepared according to Kumagai and Sakai (5) .
SDS PAGE was performed according to Laemmli (10) 
Immunological Procedures
The production of a monoclonal antibody (El2) to the 34-kD MAP was described previously by Rodionov et al. (15) . This antibody was of the igG class. Monoclonal antibodies to tubulin (Tu 0.1) and to MAP-2 (MA 1) were generously provided by Drs. P. Draber and V. Vicklicky (Institute of Molecular Genetics, Prague, Czechoslovakia).
Immunoblotting was performed according to Towbin et al. (19) as modified by Rodionov et al. (15) . Antibody-reactive components were revealed by incubation in 4-chloro-l-naphthol (0.5 mg/ml) in 50 mM Tris-HCl (pH 7.5) containing 0.05% H202.
For immunoprecipitation, total MAPs (0.3-0.4 mg/ml) or alpha-chymotrypsin-treated MAP-I (0.15-0.20 mg/ml) was incubated with El2 antibody (0.4-0.6 mg/ml) for 3 h in buffer A at room temperature. Monospecific rabbit antibody against mouse lgG was added to a final concentration of 0.5-0.7 mg/ ml, and after 30 rain of incubation at room temperature, immunoprecipitates were collected by pelleting at 150,000 g for 20 min through a layer of 4 M glycerol and 0.5 M KCI in buffer A. The precipitates were dissolved in 10% SDS and 5% 2-mercaptoethanol and analyzed by SDS gel electrophoresis. Small amounts of insoluble material usually remained in the immunoprecipirates, even after heating the samples in gel sample buffer containing 10% SDS and 10% beta-mercaptoethanol. However, the amounts of this insoluble material were small (<1%), did not contain LC-I, as determined by immunoblotting using a monoclonal antibody to LC-I (Fig. 8B) , and therefore did not interfere with our gel electrophoretic analyses of LC-1 in immunoprecipitates.
Microscopy
For immunofluoreseence staining, twice-cycled microtubules at 1.0-1.5 mg/ml in buffer A were adsorbed onto glass coverslips pretreated with poly-L-lysine (1 mg/ml). After adsorption microtubules were fixed with 4% formaldehyde in phosphate-buffered saline (PBS). Fixed microtubules were thoroughly washed with PBS, treated with I% bovine serum albumin for 30 min, and then stained with the antibodies by the indirect method. El2 antibody (ascites) was used at a concentration of ~1 mg/ml.
For electron microscopy pelleted microtubules were fixed overnight with 1% glutaraldehyde in 10 mM sodium phosphate buffer (pH 7.0) containing 1% tannic acid and postfixed with 1% OsO4. Samples were stained with uranyl acetate in ethanol at 70"C and after ethanol-acetone dehydration were embedded in Epon. Ultrathin sections stained with lead citrate (13) were examined and photographed on an Hitachi HU-I IB electron microscope (Hitachi Ltd, Tokyo) operated at 75 kV.
Materials
Alpha-chymotrypsin (type VII TLCK treated) and molecular weight markers were purchased from Sigma Chemical Co. (St. Louis, MO); phosphocellulose (P-I 1) was from Whatman Chemical Separation, Inc. (Clifton, N J); taxol was from the National Cancer Research Institute (Bethesda, MD). by densitometry of Coomassie Blue-stained polyacrylamide gels. The twofold difference in the molar ratio (one antibody/ two low molecular weight components) may be due to differences in Coomassie Blue staining, heterogeneity of the antigen, or other factors. As expected, the antibody also stained cycled brain microtubules that were fixed before examination by immunofluorescence microscopy (Fig. 3) . These observations establish that the binding of antibody to the 34-kD component of cycled brain microtubules is specific and saturable.
Results
Demonstration of Antibody Specificity
The 34-kD Component Is a Light Chain of MAP-1
We demonstrated previously that purified fractions of MAP-1 contain two low molecular weight components with molecular weights of <40 kD (7). Vallee and Davis (21) showed that the low molecular weight components co-purify with the MAP-1 heavy chain when MAP preparations are subjected to various chromatographic procedures. To confirm that MAP-1 preparations contain low molecular weight components and to show that the light chains were not binding to other MAPs such as MAP-2, we incubated antibody with a preparation of total high molecular weight MAPs and examined the composition of supernates and pellets after immunoprecipitation with a rabbit anti-mouse IgG antibody. The immunoprecipitates were observed to contain both the 34-kD component and the heavy chain of MAP-1 (Fig. 4) but did not contain MAP-2, which remained in the supernate. However, the pellets did contain a component with an electrophoretic mobility near that of MAP-2, but by immunoblotting using a MAP-2 specific antibody, it could be shown that this component was not MAP-2 itself, suggesting that it may be a proteolytic fragment of the MAP-I heavy chain. Electrophoresis of MAP-l on gradient gels in 0.1 M phosphate revealed that MAP-1 contains three principal heavy chains, as was demonstrated previously by Bloom et al. (2) . Electrophoretic analysis of immunoprecipitates prepared from a purified MAP-1 fraction revealed that the 34-kD component bound to at least two major classes (A and B) of the MAP-I heavy chains (Fig. 5 ). These observations demonstrate the specificity of binding of the 34-kD component to MAP-1 heavy chains and justify its designation as a light chain of MAP-1 (LC-l). Antibody binding experiments showed that E-12 antibody interacts with MAP-1 both in solution and on microtubule surfaces. Therefore, the site of antibody binding and the site of tubulin binding on the MAP-1 molecule may not overlap. The observation that preincubation of MAP-l with the antibody does not inhibit the ability of MAP-1 to promote tubulin polymerization in vitro is consistent with this interpretation (data not shown).
Localization of LC-1 on the Heavy Chain of MAP-1
We and others have shown previously that MAP-1 binds to the lateral surfaces of microtubules and contains a distinctive projection portion that can be distinguished by electron microscopy after tannic acid staining and thin sectioning (9, 21) . If partial proteolysis removed the projection portion of MAP-1 from microtubules as it does for MAP-2, we could use this method to determine which domain of the MAP-I heavy chain binds LC-1. When preparations of purified MAP-1 free of microtubules were digested with alpha-chymotrypsin, several peptides were formed, including a stable 120-kD fragment of the MAP-I heavy chain, LC-1, and other minor components (Fig, 6A) . When the peptide mixture was combined with taxol-stabilized microtubules containing phosphocellulose-purified tubulin (taxol microtubules) and pelleted, all of the 120-kD fragment and LC-1 were observed to bind to microtubules, as determined by sedimentation and gel electrophoresis (Fig. 6 B) . Examination of thin sections of these pellets by electron microscopy revealed that a considerable portion of the MAP-1 projection was absent (Fig, 7) , indicating that the fragments that bound-to microtubules were part of the microlubule-binding domain of MAP-I.
From this procedure alone, however, it was not possible to determine if LC-1 and the 120-kD fragment of the MAP-I heavy chain bound to microtubules independently or were associated together as a complex. To distinguish between these alternatives, we examined the composition of immunoprecipitates of a purified MAP-1 preparation after partial digestion with chymotrypsin, which produced the 120-kD fragment (Fig. 8) . The immunoprecipitates contained both LC-1 and the 120-kD heavy chain fragment, indicating that the two components are associated together in a complex. Thus, there ts no evidence to indicate that LC-I and MAF-I heavy chain Figure 7 . Removal of the projection portion of MAP-1 by digestion with alpha-chymotrypsin. Purified MAP-1 (0.2 mg/ml) was treated with alpha-chymotrypsin (1:200 enzyme/MAP1 ratio) for 3 rain in buffer A at room temperature. The reaction was arrested with 2 mM PMSF, and the digest was added to taxol-microtubules assembled from phosphocellulose-purified tubulin. Microtubules were pelleted and prepared for thin sectioning after staining with tannic acid as described in Materials and Methods. bind independently to microtubules. We also observed that the pattern of cleavage products and peptide binding to microtubules was the same when taxol-stabilized microtubules containing both MAP-1 and MAP-2 were partially digested with chymotrypsin, pelleted, and examined by gel electrophoresis and immunoblotting (Fig. 9 ). No differences in the pattern of cleavage were observed, indicating that MAP-l is cleaved similarly in both the bound and unbound states.
Discussion
With a monoclonal antibody specific for the 34-kD component (LC-I) of MAP-1 and an immunoprecipitation assay, we have been able to demonstrate that LC-1 is tightly and specifically bound to MAP-1 heavy chain and that LC-1 shows no affinity for MAP-2. Saturating amounts of antibody to LC-I were observed to precipitate most of the heavy chain components of MAP-I, including the two principal A and B isoforms of MAP-1. However, resolution of the immunoprecipitates was insufficient to determine if all of the MAP-1 heavy chain species were present. This indicates that at least the A and B variants of MAP-1 heavy chain contain light chain binding sites and are structurally related, which is in agreement with previous comparisons by peptide mapping (2) . This observation also suggests that most of the MAP-1 heavy chains are complexed with LC-1. We also observed that LC-2 was removed from solution by immunoprecipitation, Figure 8 . lmmunoprecipitation of chymotryptic fragments of MAP-I. Aliquots of purified MAP-1 (40 ~g) were digested for 0, I, and 2 rain at room temperature with alpha-chymotrypsin (0. lug), arrested with 2 mM PMSF, and immunoprecipitated as described in the legend to but this observation was difficult to quantitate by gel electrophoresis of immunoprecipitates, since LC-2 was usually obscured by the presence of antibody light chains. It therefore appears likely that MAP-1 heavy chains, LC-I, and LC-2 are associated together in a complex.
Alpha-chymotrypsin cleaves MAP-1 into peptides, some of which retain the ability to bind to microtubules. However, the sizes and relative amounts of the microtubule-binding peptides are different from those obtained from MAP-2 using the same enzyme treatment. This agrees with the observations made previously that MAP-l and MAP-2 are different proteins as determined by partial proteolysis with Staphylococcus protease V8 or alpha-chymotrypsin and peptide analysis on Cleveland gels (7) . Under conditions of limited proteolysis with chymotrypsin, MAP-2 is cleaved into a major 240-kD fragment that no longer binds to microtubules (projection portion) and 32-39-kD fragments that retain microtubulebinding activity (microtubule-binding domain) (20) . In contrast, we observed that MAP-1 is cleaved into a large 120-kD proteolysis-resistant fragment that associates with both LC-1 and LC-2 and contains microtubule-binding activity. A number of other peptides of intermediate to low molecular weight were also generated but did not contain microtubule-binding activity. Since LC-1 is not strongly affected by limited proteolysis and is associated with the 120-kD fragment, this molec- So far it has not been possible to identify which components in the microtubule-binding domain of MAP-1 contain microtubule-binding activity. Our antibody does not block the binding of MAP-1 to microtubules, inhibit MAP-1 induced polymerization of tubulin, or displace MAP-1 from preformed microtubules containing MAP-1. Therefore it is possible that microtubule-binding activity is not contained in LC-I but in other components such as the MAP-1 heavy chain or LC-2. Alternatively, LC-1 may bind to microtubules but at a site not blocked by the presence of bound antibody. Vallee and Davis (21) reported previously that MAP-I heavy chain, isolated by ion-exchange chromatography in the presence of 6 M urea, binds weakly to microtubules, but it was not clear from this study if the low binding activity was due to the removal of MAP-1 light chains or to partial denaturation of the protein. To answer this question definitively, it would be desirable to examine the microtubule-binding activity of native MAP-1 heavy chains in the presence and absence of MAP-1 light chains.
Although we can demonstrate the selective binding of LC-1 to the heavy chains of MAP-1 and localize the light chain binding site to a 120-kD peptide of MAP-l, we have so far been unable to demonstrate that LC-1 is specifically localized on microtubules in situ. LC-1 was not detected by immunoblotting and microtubules were not labeled with the antibody in several different types of tissue culture cells (mouse embryo fibroblasts, bovine tracheal epithelial cells [FBT cell line] and CHO cells). It is possible that MAP-1 light chains in these cells are present in low amounts, or contain different antigenic sites, or are absent. However, it may be possible to culture neuronal cells that contain more MAP-1 to determine if LC-1 is localized on microtubules in situ. With cultures of neuronal cells it may also be possible to inject living cells with antibody, and by observing subsequent cellular behavior, ascertain if LC-1 is important for determining some of the functions of microtubules in vivo. Further work will be required to explore these possibilities.
